|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:academic_advisor
|
leading researchers
|
|
gptkbp:acquisition
|
gptkb:TCR2_Therapeutics
|
|
gptkbp:advances
|
gene editing
|
|
gptkbp:application
|
gptkb:cancer_treatment
|
|
gptkbp:business_model
|
biotech startup
|
|
gptkbp:ceo
|
gptkb:Rachel_Haurwitz
|
|
gptkbp:clinical_trial
|
active
ongoing
Phase 1
therapeutic applications
|
|
gptkbp:clinical_trials_location
|
gptkb:United_States
|
|
gptkbp:collaboration
|
gptkb:Stanford_University
gptkb:University_of_California,_Berkeley
|
|
gptkbp:collaborations
|
gptkb:UCSF
academic institutions
|
|
gptkbp:collaborator
|
gptkb:Cure_Vac
|
|
gptkbp:community_engagement
|
patient advocacy
|
|
gptkbp:community_impact
|
healthcare innovation
|
|
gptkbp:development
|
CRISPR tools
|
|
gptkbp:focus
|
gptkb:CRISPR_technology
|
|
gptkbp:founded
|
gptkb:2011
|
|
gptkbp:founder
|
gptkb:Jennifer_Doudna
|
|
gptkbp:funding
|
gptkb:venture_capital
grants
|
|
gptkbp:goal
|
improve patient outcomes
|
|
gptkbp:has_advisory_board
|
experts in the field
|
|
gptkbp:has_culture
|
innovation-driven
|
|
gptkbp:headquarters
|
gptkb:Berkeley,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Caribou Biosciences
|
|
gptkbp:industry
|
healthcare
|
|
gptkbp:innovation
|
CRISPR applications
|
|
gptkbp:instruction_set
|
multiple candidates
|
|
gptkbp:invention
|
gptkb:CRISPR_technology
|
|
gptkbp:investment
|
$45 million
institutional investors
|
|
gptkbp:investment_focus
|
therapeutics
|
|
gptkbp:is_a_platform_for
|
CRISPR-based
|
|
gptkbp:leadership
|
diverse team
|
|
gptkbp:market_launch
|
new therapies
|
|
gptkbp:marketing_strategy
|
partnerships
collaborative research
|
|
gptkbp:mission
|
transform medicine
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Novartis
biopharma companies
|
|
gptkbp:pathway
|
FDA approval
|
|
gptkbp:product
|
CAR-T therapies
therapeutic candidates
|
|
gptkbp:publications
|
peer-reviewed journals
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
|
|
gptkbp:research
|
gene therapies
genome editing technologies
|
|
gptkbp:research_areas
|
oncology
hematology
|
|
gptkbp:research_focus
|
autoimmune diseases
immuno-oncology
cancer immunotherapy
cell therapies
|
|
gptkbp:research_initiative
|
genetic disorders
|
|
gptkbp:service
|
biopharmaceuticals
|
|
gptkbp:stock_symbol
|
gptkb:CRBU
|
|
gptkbp:strategic_goals
|
expand product pipeline
transforming healthcare
|
|
gptkbp:technology
|
gptkb:CRISPR-Cas9
genome editing
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:vision
|
genome editing for all
|
|
gptkbp:website
|
www.cariboubio.com
|
|
gptkbp:bfsParent
|
gptkb:Jennifer_Doudna
|
|
gptkbp:bfsLayer
|
3
|